Stephan Busque

Stephan Busque

Auto-generated profile, based on publicly available information

Stephan Busque

Division of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Stanford, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SBStephan Busque
Stephan Busque
JSJohn D. Scandling
John D. Scandling
RLRobert Lowsky
Robert Lowsky
JSJudith Shizuru
Judith Shizuru
KJKent Jensen
Kent Jensen
SSSamuel Strober
Samuel Strober
Persistent mixed chimerism protects against rejection of HLA-matched and mismatched kidney transplants without graft-versus-host disease.

6 February 2025 in American Journal of Transplantation
Verified
Journal Article
Closed access
DKDixon B. Kaufman
Dixon B. Kaufman
SASanjeev K. Akkina
Sanjeev K. Akkina
MSMark.D. Stegall
Mark.D. Stegall
JPJames B. Piper
James B. Piper
AGA. Osama Gaber
A. Osama Gaber
DBDaniel Brennan
Daniel Brennan

23 July 2020 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
AWAileen X. Wang
Aileen X. Wang
OCOrlando Quintero Cardona
Orlando Quintero Cardona
DHDora Y. Ho
Dora Y. Ho
SBStephan Busque
Stephan Busque
CLColin R. Lenihan
Colin R. Lenihan
Solid organ transplant recipients are at risk for infectious complications due to chronic immunosuppression. The outbreak of coronavirus disease 2019 (COVID‐19) in the United States has raised growing concerns for the transplant patient population. We seek to add to the current limited literature on COVID‐19 in transplant recipients by describing the clinical course of two kidney transplant recipients with SARS‐CoV‐2 infection monitored by both RT‐PCR and serology. Through careful adjustment of their immunosuppression regimen, both patients had excellent recovery with intact graft function and development of anti‐SARS‐CoV‐2 antibodies.

27 January 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
AWAileen X. Wang
Aileen X. Wang
SBStephan Busque
Stephan Busque
JKJamie Kuo
Jamie Kuo
USUpinder Singh
Upinder Singh
KRKatharina Röeltgen
Katharina Röeltgen
CLColin R. Lenihan
Colin R. Lenihan
Background: Morbidity and mortality associated with coronavirus disease 2019 (COVID-19) infection in kidney transplant recipients are high and early outpatient interventions to prevent progression to severe disease are needed. SARS-CoV-2 neutralizing mAbs, including bamlanivimab and casirivimab-imdevimab, received emergency use authorization in the United States in November 2020 for treatment of mild to moderate COVID-19 disease. Methods: We performed a retrospective analysis of 27 kidney transplant recipients diagnosed with COVID-19 between July 2020 and February 2021 who were treated with bamlanivimab or casirivimab-imdevimab and immunosuppression reduction. We additionally identified 13 kidney transplant recipients with COVID-19 who had mild to moderate disease at presentation, who did not receive mAbs, and had SARS-CoV-2 serology testing available. Results: There were no deaths or graft failures in either group. Both infusions were well tolerated. Four of the 27 patients treated with mAbs required hospitalization due to COVID-19. Four of 13 patients who did not receive mAbs required hospitalization due to COVID-19. Patients who received mAbs demonstrated measurable anti–SARS-CoV-2 IgG with angiotensin-converting enzyme 2 (ACE2) receptor blocking activity at the highest level detectable at 90 days postinfusion, whereas ACE2 blocking activity acquired from natural immunity in the mAb-untreated group was weak. Conclusions: Bamlanivimab and casirivimab-imdevimab combined with immunosuppression reduction were well tolerated and associated with favorable clinical outcomes in kidney transplant recipients diagnosed with mild to moderate COVID-19.

18 February 2025 in ImmunoHorizons
Verified
Journal Article
Open access
SKSangeeta Kowli
Sangeeta Kowli
SMSheroy Minocherhomji
Sheroy Minocherhomji
OMOlivia M. Martinez
Olivia M. Martinez
SBStephan Busque
Stephan Busque
HLHerve Lebrec
Herve Lebrec
HMHolden T. Maecker
Holden T. Maecker
Chronic immunosuppressive therapies are crucial in organ transplantation but can increase the risk of opportunistic infections and cancer over time. We investigated immune status changes in 10 kidney transplant patients and 11 age-matched healthy adults using broad in vitro stimulation of subject-derived peripheral blood mononuclear cells followed by mass cytometry by time of flight over 6 mo. Overall, the immune cells of transplant patients exhibited increased CD8+ T cell activation and differentiation compared with healthy donors, with elevated CD8+ CD57+, MIP-1β, and interferon γ production (P < 0.05, P < 0.05, and P < 0.01, respectively). CD107a and granzyme B expression were increased in CD8+ T cells and CD56bright natural killer cells (P < 0.05 and P < 0.01, respectively), while T regulatory cells had decreased interleukin-10 production (P < 0.05). These changes indicated a proinflammatory environment influenced by induction therapy and ongoing maintenance drugs. Additionally, transplant recipients displayed signs of immune modulation, including decreased tumor necrosis factor α, interferon γ, and MIP-1β expression in γδT cells (P < 0.05 and P < 0.01), and reduced interleukin-17 and granulocyte-macrophage colony-stimulating factor expression in CD8+ T memory cell subsets (P < 0.05). The diverse functional changes underscore the importance of comprehensive immune status profiling for optimizing individual treatment strategies and developing better immunosuppressants that specifically target activated cell populations.

15 May 2026 in American Journal of Transplantation
Verified
Journal Article
Closed access
TNToshihiro Nakayama
Toshihiro Nakayama
DADaniel J. Ahn
Daniel J. Ahn
AAAntony Attia
Antony Attia
KBKliment K. Bozhilov
Kliment K. Bozhilov
VKVarvara A. Kirchner
Varvara A. Kirchner
TPThomas A. Pham
Thomas A. Pham